A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas
Lymphatics · 05.01.2024 · 2 (1) · 10-24
DOI: 10.3390/lymphatics2010002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lymphatics, online erschienen am 05.01.2024. Verfasst von Himil Mahadevia und 4 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of lymphomas by improving the survival of patients, particularly in conjunction with chemotherapy. Until recently, the gold standard was based on the utilization of Rituximab (RTX) combined with chemotherapy. With our better understanding of monoclonal antibody (mAb) engineering, anti-CD20 mAb therapy has evolved to enhance clinical outcomes by improving pharmacokinetics, safety, activity and immunogenicity. Efforts to improve the on-targeting CD20 expressed on lymphomas through novel bioengineering techniques have led to the development of newer anti-CD20 mAbs that have accentuated complement-dependent cytotoxicity (CDC), antibody-dependent cell medicated cytotoxicity (ADCC), and/or a direct killing effect. There are several anti-CD20 monoclonal antibodies that have been evaluated for the treatment of lymphomas, some of which are now approved in addition to RTX.
Zitieren
APA
Mahadevia, H., Ananthamurugan, M., Shah, K., Desai, A., & Shrestha, A. (2024). A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas. Lymphatics, 2(1), 10-24. https://doi.org/10.3390/lymphatics2010002
Vancouver
Mahadevia H, Ananthamurugan M, Shah K, Desai A, Shrestha A. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas. Lymphatics. 2024;2(1):10-24. doi:10.3390/lymphatics2010002
BibTeX
@article{Mahadevia2024,
author = {Mahadevia, Himil and Ananthamurugan, Mirdhula and Shah, Kashish and Desai, Atharva and Shrestha, Anuj},
title = {A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas},
journal = {Lymphatics},
year = {2024},
volume = {2},
number = {1},
pages = {10--24},
doi = {10.3390/lymphatics2010002}
}
EUVIMED